Accreditation/Credit Designation

Physicians’ Education Resource^®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource^®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.

This activity, COPE Activity Number 121364, is accredited by COPE for continuing education for optometrists.

Acknowledgment of Support

This activity is supported by an educational grant from Allergan.

Clinical Briefings™: Latest Advances in Presbyopia with Innovative Therapies on the Horizon

Release Date: April 15, 2021
Expiration Date: April 15, 2022

Activity Overview

This online activity is designed to provide a concise and focused overview of both traditional strategies and investigational pharmaceutical agents for the management of presbyopia. The engaging multimedia format of this program includes audio commentary from an expert thought leader integrated with text-based elements.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Allergan.

Instructions for This Activity and Receiving Credit

Complete the activity (including pre- and post-activity assessments).
Answer the evaluation questions.
Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This online educational activity is directed toward ophthalmologists, optometrists, and other health care professionals involved in the management of patients with presbyopia.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Explain current and historical treatments for presbyopia and how different modalities affect patients’ quality of life
Describe the mechanisms of action of investigational topical therapies for presbyopia as they relate to the pathophysiology of the disease
Evaluate the efficacy and safety of emerging investigational topical therapies for presbyopia

Faculty, Staff, and Planners’ Disclosures

In accordance with accreditation guidelines set forth by ACCME and the Council on Optometric Practitioner Education (COPE), PER^® identified and mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity.

Faculty

Francis S. Mah, MD
Director of Cornea Service
Co-Director of Refractive Surgery Service
Division of Ophthalmology
Department of Surgery
Scripps Clinic
La Jolla, CA

Disclosures: Consultant: Allergan, Egenouia, Ocular Science, Novartis. Speakers Bureau: Allergan, Egenouia, Ocular Science, Novartis. Stock/Stakeholder: Ocular Science.

The staff of Physicians’ Education Resource^®, LLC (PER^®), have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.